Skip to main content

Table 3 Adverse Events according to genotype (n =88)

From: A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis

Genotype

Leukopenia, ≥ grade 2

Neutropenia, ≥ grade 2

Anemia, ≥ grade 2

Diarrhea, ≥ grade 2

Anorexia, ≥ grade 2

Abd pain, ≥ grade 2

Stomatitis, ≥ grade 2

Any grade 3 toxicity

CYP2A6

 w/w (n = 22)

0 (0%)

0 (0%)

1 (4.6%)

3 (13.6%)

1 (4.6%)

4 (18.2%)

0 (0%)

7 (31.8%)

 w/v (n = 37)

4 (10.8%)

3 (8.1%)

4 (10.8%)

4 (10.8%)

4 (10.8%)

2 (5.4%)

0 (0%)

6 (16.2%)

 v/v (n = 29)

6 (20.7%)

3 (10.3%)

4 (13.8%)

7 (24.1%)

0 (0%)

3 (10.3%)

6 (15.8%)

7 (24.1%)

  P valuea

0.022†

0.161

0.291

0.269

0.398

0.428

0.012†

0.595

UMPS G638T

 GG (n = 41)

5 (12.2%)

3 (7.3%)

6 (14.6%)

4 (9.8%)

1 (2.4%)

2 (4.9%)

3 (7.3%)

8 (19.5%)

 GC (n = 39)

5 (12.8%)

3 (7.7%)

2 (5.1%)

6 (15.4%)

3 (7.7%)

5 (12.8%)

2 (5.1%)

7 (18.0%)

 CC (n = 8)

0 (0.0%)

0 (0.0%)

1 (12.5%)

4 (50.0%)

1 (12.5%)

2 (25.0%)

1 (12.5%)

5 (62.5%)

  P valuea

0.518

0.625

0.378

0.018†

0.183

0.067

0.557

0.078

ABCB1 C1236T

 CC (n = 10)

1 (10.0%)

1 (10.0%)

1 (10.0%)

2 (20.0%)

0 (0.0%)

0 (0.0%)

0 (0%)

2 (20.0%)

 CT (n = 49)

5 (10.2%)

2 (4.08%)

5 (10.2%)

7 (14.3%)

3 (6.1%)

5 (10.2%)

5 (10.2%)

12 (24.5%)

 TT (n = 27)

4 (14.8%)

3 (11.1%)

3 (11.1%)

5 (18.5%)

2 (7.4%)

4 (14.8%)

1 (3.7%)

6 (22.2%)

  P valuea

0.584

0.584

0.902

0.914

0.459

0.214

0.900

0.985

ABCB1 C3435T

 CC (n = 35)

3 (8.6%)

2 (5.7%)

2 (5.7%)

4 (11.4%)

2 (5.7%)

4 (11.4%)

2 (5.7%)

9 (25.7%)

 CT (n = 42)

6 (14.3%)

3 (7.1%)

6 (14.3%)

9 (21.4%)

2 (4.8%)

4 (9.5%)

4 (9.5%)

9 (21.4%)

 TT (n = 11)

1 (9.1%)

1 (9.1%)

1 (9.1%)

1 (9.1%)

1 (9.1%)

1 (9.1%)

0 (0%)

2 (18.2%)

  P valuea

0.717

0.689

0.447

0.723

0.804

0.776

0.819

0.559

ABCB1 G2677T

 GG (n = 33)

3 (9.1%)

2 (6.1%)

2 (6.1%)

4 (12.1%)

2 (6.1%)

3 (9.1%)

2 (6.1%)

9 (27.3%)

 GT (n = 26)

3 (11.5%)

2 (7.7%)

5 (19.2%)

5 (19.2%)

2 (7.7%)

3 (11.5%)

3 (11.5%)

5 (19.2%)

 TT (n = 26)

3 (11.5%)

2 (7.7%)

2 (7.7%)

5 (19.2%)

1 (3.9%)

3 (11.5%)

1 (3.9%)

6 (23.1%)

  p valuea

0.754

0.802

0.754

0.450

0.745

0.754

0.797

0.678

ABCB1 haplotype

 *1/*1 (n = 7)

1 (14.29%)

1 (14.29%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (14.3%)

 *1/v (n = 36)

3 (8.33%)

1 (2.78%)

5 (13.89%)

3 (8.33%)

4 (11.11%)

4 (11.11%)

4 (11.11%)

10 (27.8%)

 v/v (n = 42)

5 (11.90%)

4 (9.52%)

4 (9.52%)

2 (4.76%)

5 (11.90%)

5 (11.90%)

2 (4.76%)

9 (21.4%)

  P value

0.872

0.727

0.872

0.573

0.966

0.756

0.477

0.925

  1. Abbreviations: CYP2A6 cytochrome P 2A6, w wild type allele, v variant allele, Abd abdominal, UMPS uridine monophosphate synthetase, ABCB1 ATP-binding cassette B1
  2. atest for trend by Cuzick’s test
  3. † P value <0.05
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us